ABVC — ABVC Biopharma Share Price
Last Trade - 00:00- $56.83m
- $57.93m
- $0.67m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.01 | 0.7 | 0.48 | 0.81 | 0.89 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ABVC BioPharma, Inc. (ABVC), formerly American BriVision (Holding) Corporation, is a biotechnology company focused on the development of drugs and medical devices. The Company is focused on developing its pipeline by tracking medical discoveries or medical device technologies in research institutions. ABVC has approximately six drugs and three medical devices in development. The Company's pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1702, ABV-1703, ABV-1601, ABV-1701, ABV-2001 and ABV-2002. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine. ABVC is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). ABV-1702 is to treat myelodysplastic syndromes (MDS). ABVC developed an indication, ABV-1703, for Pancreatic Cancer. The Company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy.
Directors
- Eugene Jiang CHM (32)
- Howard Doong CEO (61)
- Chihliang An (38)
- Chi-Hsin King (70)
- Chang-Jen Jiang (63)
- Tsang-Ming Jiang (58)
- Tsung-Shann Jiang (65)
- Hwalin Lee (84)
- Yen-Hsin Chou IND (30)
- Shin-Yu Miao (56)
- Yoshinobu Odaira (71)
- Norimi Sakamoto IND (48)
- Shih-Chen Tzeng (62)
- Ming-Fong Wu IND (43)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- February 6th, 2002
- Public Since
- December 17th, 1998
- No. of Shareholders
- 711
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 26,681,638
- Address
- 44370 Old Warm Springs Blvd, FREMONT, 94538-6148
- Web
- https://abvcpharma.com/
- Phone
- +1 5106680881
- Auditors
- KCCW Accounting Corp
Latest News for ABVC
Upcoming events for ABVC
Similar to ABVC
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
ADITXT ORD
NASDAQ Capital Market
FAQ
As of Today at 19:54 UTC, shares in ABVC Biopharma are trading at $2.13. This share price information is delayed by 15 minutes.
Shares in ABVC Biopharma last closed at $2.13 and the price had moved by -47.41% over the past 365 days. In terms of relative price strength the ABVC Biopharma share price has underperformed the S&P500 Index by -60.1% over the past year.
There is no consensus recommendation for this security.
ABVC Biopharma does not currently pay a dividend.
ABVC Biopharma does not currently pay a dividend.
ABVC Biopharma does not currently pay a dividend.
To buy shares in ABVC Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.13, shares in ABVC Biopharma had a market capitalisation of $56.83m.
Here are the trading details for ABVC Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ABVC
Based on an overall assessment of its quality, value and momentum ABVC Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ABVC Biopharma is $9.50. That is 346.01% above the last closing price of $2.13.
Analysts covering ABVC Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.19 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ABVC Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -61.6%.
As of the last closing price of $2.13, shares in ABVC Biopharma were trading -53.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for ABVC Biopharma.
ABVC Biopharma's management team is headed by:
- Eugene Jiang - CHM
- Howard Doong - CEO
- Chihliang An -
- Chi-Hsin King -
- Chang-Jen Jiang -
- Tsang-Ming Jiang -
- Tsung-Shann Jiang -
- Hwalin Lee -
- Yen-Hsin Chou - IND
- Shin-Yu Miao -
- Yoshinobu Odaira -
- Norimi Sakamoto - IND
- Shih-Chen Tzeng -
- Ming-Fong Wu - IND
We do not have data on ABVC Biopharma's shareholders